All stories
Jump to date
Tuesday, October 6 · 15 stories
- Federal Policy
HHS Finalizes Updated Hospital Price Transparency Rule
HHS, the Employee Benefits Security Administration, and the IRS finalized amendments to the hospital price transparency rules first established during President Trump's first term. The changes aim to make hospital pricing data more accessible and understandable for patients and other users of the data. The rule applies broadly to hospitals and group health plans rather than specifically to Medicaid programs. Further detail on effective dates and specific data requirements was not included in the source material.

- Federal Policy
Diaper Bank Founder Urges Opposition to Head Start Rule Cuts
In a commentary piece, National Diaper Bank Network founder Joanne Samuel Goldblum argues against a proposed federal rule that would shrink Head Start's regulatory requirements from 133 pages to about a dozen, eliminating mandates for diapers, formula, toothbrushes, class size, and staffing ratios. She links the proposal to earlier federal office closures and argues it reflects a broader rollback of Great Society-era safety net programs including Medicaid and SNAP. Goldblum cites National Diaper Bank Network research showing nearly half of young U.S. families struggle to afford diapers and that diaper assistance reduces pediatric sick visits, generating Medicaid savings. She urges readers to submit public comments opposing the rule, noting the comment period closes October 6.

- Federal Policy
CMS Issues Rule Cleaning Up Health Price Transparency Data
The Trump administration released new regulations requiring health insurers to publish cleaner, more usable spreadsheets of negotiated prices paid to hospitals and doctors, removing extraneous data that had made prior transparency files difficult to use. CMS Administrator Mehmet Oz said officials will begin developing a system for disclosing prescription drug pricing data next month, with a final plan expected by next May and enforcement by the end of 2027. The move follows last year's decision to delay finalizing drug price disclosure rules, which benefited drug companies and pharmacy benefit managers. The rule applies broadly to health insurers, including those operating Medicaid managed care plans.
- Federal Policy
House E&C Republicans Unveil Anti-Fraud Bill Package
In its Health Care Week in Review, Alston & Bird reports that House Energy and Commerce Committee Republicans introduced a package of bills targeting health care fraud, alongside news that CMS finalized the GLOBE Model. The digest also compiles other recent federal regulatory notices, congressional committee actions, and health policy reports and analyses from the past week. Details on specific bill provisions, the GLOBE Model's scope, and applicable timelines are not provided in this summary-level roundup. Readers should consult the full digest for specifics on each item, including any Medicaid program integrity provisions within the fraud package.
- Federal Policy
Fact-Check Disputes Trump's Claims on Medicaid Drug Savings
In a FactCheck.org analysis, the organization reports that President Trump, CMS Administrator Mehmet Oz, and HHS Secretary Robert F. Kennedy Jr. have overstated likely Medicaid savings from "most favored nation" drug pricing deals with pharmaceutical manufacturers. Trump cited a Council of Economic Advisers estimate of $64 billion in savings over 10 years, split between federal and state governments, but experts including KFF's Robin Rudowitz and Georgetown's Edwin Park say key details, which drugs are covered, how many states will participate, and deal duration, remain confidential and unclear. The administration's GENEROUS model reportedly covers "hundreds" of drugs, with CMS estimating up to $5.2 billion in annual rebates depending on state and drug participation. FactCheck.org notes the White House's own projections put initial state savings at under 2% of annual Medicaid drug spending, diminishing over time.

Monday, October 5 · 15 stories
- Federal Policy
White House Pledges $90 Medicare Part B Rebate to Seniors
The White House has announced plans to send a $90 direct deposit or check to roughly 20.8 million Medicare beneficiaries this month, framed as a rebate tied to Medicare Part B. The payment is the latest in a series of cash payments promised by the administration ahead of the November midterm elections. Details on funding mechanism, eligibility criteria, and distribution timeline were not fully specified in available reporting. The move primarily affects Medicare beneficiaries rather than Medicaid enrollees, though dual-eligible individuals covered by both programs could see incidental effects.

- Federal Policy
Medicare Improvement Fund Sends $90 One-Time Payments to Seniors
The Trump administration is distributing one-time $90 payments to qualifying Medicare beneficiaries, funded through the Medicare Improvement Fund, arriving as direct deposits or paper checks. The source does not detail specific eligibility criteria beyond framing the payments as targeted at seniors enrolled in Medicare. No information is provided on an application process, exact distribution timeline, or whether dual-eligible Medicaid beneficiaries are included. Details on funding mechanism and scope remain limited in the reporting.

- Federal Policy
GAO Finds Part D Insurers Steer Enrollees to Owned Pharmacies
A GAO report examines four large, vertically integrated Medicare Part D plan sponsors that own pharmacy benefit managers and pharmacies, finding their owned pharmacies handled about 24% of drug utilization and 28% of pharmacy payments in 2023. Owned pharmacies were primarily mail-order, while non-owned pharmacies were primarily retail. For at least 94% of the 100 most commonly used drugs, payments and beneficiary cost sharing were lower at owned pharmacies, creating a financial incentive for enrollees to use plan-affiliated pharmacies, a practice GAO calls steering. For some high-cost brand-name drugs, however, cost sharing was up to $340 higher at owned pharmacies. Findings are based on 2023 CMS data and are not generalizable beyond the four selected sponsors or year.
- Federal Policy
White House Sends $90 Payments to Traditional Medicare Enrollees
The White House announced that more than 20 million traditional Medicare enrollees will receive one-time $90 payments in early October to help offset Part B premiums, funded through the Medicare Improvement Fund. Payments go via direct deposit or mailed check; enrollees whose premiums are already covered by Medicaid, those paying income-related adjustment amounts, Medicare Advantage enrollees, and people living outside the U.S. are not eligible. The fund, established in 2008, had never previously issued payments despite fluctuating congressional funding levels. The action follows separate $500 payments sent to over 950,000 people over claimed ACA exchange overcharges.
- Federal Policy
Senate Democrats Demand Answers on Preventive Task Force Overhaul
Sen. Angus King (I-Maine) and 16 other Senate Democrats sent a letter to HHS Secretary Robert F. Kennedy Jr. demanding answers about his recent overhaul of the U.S. Preventive Services Task Force, the expert panel that determines which preventive services insurers must cover without cost-sharing. The senators are pressing HHS on the rationale and process behind the changes to the panel's composition. No deadline for HHS response is specified in the available reporting. The task force's recommendations shape coverage mandates across commercial insurance and have downstream influence on Medicaid benefit design and quality benchmarks.

- Federal Policy
RFK Jr., Oz to Unveil Health Price Transparency Initiative
HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz are set to announce new health care price transparency efforts Monday, joined by Labor Secretary Keith Sonderling, Deputy Treasury Secretary Francis Brooke, and the FTC Chair. The announcement spans multiple federal agencies, suggesting a coordinated cross-government push rather than a single CMS rule. Details on the specific policy actions, scope, and effective dates were not available ahead of the event. The multi-agency involvement signals the initiative may touch pricing disclosure requirements across commercial, employer-sponsored, and government health coverage.

- Federal Policy
CMS Finalizes Transparency in Coverage Rule Updates
CMS has issued a fact sheet summarizing final rules under the Transparency in Coverage framework (CMS 9882-F), which govern how health plans must disclose pricing and cost-sharing information to consumers. The rules primarily apply to group health plans and health insurance issuers in the individual and group markets, requiring public disclosure of negotiated rates, out-of-network allowed amounts, and prescription drug pricing data. Affected plans must build compliance into their operations according to the applicable effective dates outlined in the rule. The requirements matter for payers and purchasers navigating price transparency obligations, though the rule is centered on commercial and group market coverage rather than Medicaid.
- Federal Policy
CMS Finalizes Rule Expanding Price Transparency, Coverage Comparison Tools
CMS announced new regulations intended to make it easier for consumers to find, compare, and report healthcare pricing and coverage information. The rule builds on existing hospital and payer price transparency requirements, aiming to improve enforcement and usability of published pricing data. Affected stakeholders include hospitals, health plans, and insurers subject to transparency mandates, as well as consumers seeking cost estimates. CMS did not specify a Medicaid-specific component in this release, though managed care plans operating across markets may face overlapping compliance obligations.
- Federal Policy
CMS Finalizes Overhauled Price Transparency Rules for Payers
CMS, along with the Labor and Treasury departments, finalized a rule overhauling price transparency requirements for health plans and self-insured employers, revising regulations first established in 2020. The rule eliminates so-called "ghost rates" for services providers rarely perform, consolidates in-network rate files by provider network rather than by plan, lowers the claims threshold for reporting out-of-network allowed amounts, and requires a named executive to attest to data accuracy. The rule takes effect Dec. 5, 2026, with most data requirements phased in through 2027, including attestation and file changes by March 2027 and taxonomy/utilization file requirements by September 2027. Regulators declined to require consumer-friendly cost summaries or a "what changed" file, citing limits on reflecting individual cost-sharing.
- Federal Policy
Report Compares Rural, Urban Health Center Patients and Funding
A research brief analyzes 2025 national data from the Uniform Data System to compare patient populations and financing between rural and urban community health centers. It examines how these centers differ in payer mix, patient demographics, and revenue sources, and considers how recent federal policy changes could affect their financial stability. The brief does not describe a specific regulatory action but synthesizes existing UDS data to project potential impacts on health center operations going forward.
- Federal Policy
Grassley Urges Trump Administration to Finalize Kratom Rule
Sen. Chuck Grassley (R-Iowa) publicly pressed the Trump administration to finalize a proposed rule restricting sale of 7-hydroxymitragynine (7OH), a concentrated kratom compound, calling the substance deadly and demanding it be pulled from gas stations, vape shops, and other retail outlets. The statement does not specify a new regulatory action by the administration, but amplifies pressure on FDA/DEA to move from proposed to final rule status. No effective date is given, as the underlying rule remains unfinalized. The push concerns a substance regulated outside typical Medicaid pharmacy channels, though it intersects with broader opioid-use and behavioral health policy concerns.

- Federal Policy
CMS Issues FAQ on Medicare Improvement Fund Premium Rebate
CMS published a frequently-asked-questions fact sheet explaining the Medicare Improvement Fund Premium Rebate. The document addresses how the rebate works and who qualifies for it under Medicare, clarifying operational and eligibility questions for beneficiaries and stakeholders. No specific effective date or dollar figures are detailed beyond the FAQ format itself. The guidance is relevant primarily to Medicare administration rather than Medicaid.
- Federal Policy
CMS Opens 60-Day Comment Period on Information Collection Request
CMS published a Federal Register notice seeking public comment on a proposed information collection activity, as required under the Paperwork Reduction Act of 1995. The notice does not specify the particular program or data collection at issue beyond the standard PRA procedural requirements. Commenters have 60 days to weigh in on the necessity, burden estimates, and clarity of the proposed collection, as well as suggestions for reducing reporting burden through automation or other means. This is a routine procedural step CMS must take before implementing or renewing any information collection requirement.
- Federal Policy
CMS Launches Portal for 340B Part D Claims Data Submissions
CMS opened its Medicare Part D Claims Data 340B Repository on Oct. 1 for voluntary submissions, ahead of a proposed Jan. 1, 2027 deadline when submissions would become mandatory for 340B covered entities and their third-party administrators. The repository collects data elements from Part D 340B claims tied to the Medicare Prescription Drug Inflation Rebate Program. The launch coincides with other Jan. 1, 2027 changes, including 15 additional drugs moving to negotiated Medicare prices, the CY 2027 Part D benefit redesign, and a planned 340B rebate pilot shifting some covered entities to a post-sale rebate model. It also arrives amid disputes between drugmakers like Eli Lilly and Johnson & Johnson, which require direct claims-data submission from covered entities, and hospital groups and states that have challenged or restricted that practice; a CMS-run repository offers an alternative compliance path.
- Federal Policy
HRSA Approves 10 Drugmakers for 340B Rebate Pilot
HRSA announced Oct. 1 that it has approved 10 manufacturers, including AbbVie, Amgen, AstraZeneca, Merck and Pfizer, to join a revised 340B Rebate Model Pilot Program covering drugs like Eliquis, Jardiance and Enbrel. Starting Jan. 1, 2027, covered entities will keep buying through existing 340B wholesaler accounts at wholesale acquisition cost but submit limited claims data within 45 days so manufacturers can pay or deny rebates within 10 days; denials cannot be based on eligibility, diversion or Medicaid duplicate-discount concerns, which must go through separate audit channels. This is a reworked version of a pilot a federal court in Maine previously vacated and remanded to HRSA. HRSA will publish periodic implementation findings with a final evaluation due by April 2028, while the AHA says it opposes the program and is weighing options to stop it.